BioXcel Therapeutics, Inc.
BTAIQ- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001720893
No open-market purchases or sales by BioXcel Therapeutics, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $8.69M in total; Oaktree Capital is the only superinvestor holding it.
Superinvestors holding BTAIQ, Q2 2026
1 superinvestor reports holding BioXcel Therapeutics, Inc. on Form 13F, worth $1.95M in total. Weight is BioXcel Therapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Oaktree CapitalHoward Marks | <0.1% | 1,380,248 | $1.95M | Added+472.3% |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of BTAIQ each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end
- Added
- Oaktree Capital (+472.3%)
Q2 2025
1 superinvestor holding at quarter end